Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates

Clinical Immunology

Volumn 139, Issue 2, 2011, Pages 185-192

  Simon, J K ^a,b,c   Maciel, M ^a,d   Weld, E D ^a,b   Wahid, R ^a   Pasetti, M F ^a   Picking, W L ^e   Kotloff, K L ^a,b   Levine, M M ^a,b   Sztein, M B ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

^c NanoBio Corporation   (United States)

^d NAVAL MEDICAL RESEARCH CENTER   (United States)

^e OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

B cell memory; IgA; Immunoglobulin A; Mucosal immunity; Shigella; Vaccine

Indexed keywords

IMMUNOGLOBULIN A; LIPOPOLYSACCHARIDE; LIVE VACCINE; SHIGELLA VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; FECES; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MEMORY CELL; NORMAL HUMAN; PRIORITY JOURNAL; SERUM; SHIGELLA FLEXNERI; SINGLE DRUG DOSE; VACCINATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODY FORMATION; ANTIGENS; ANTIGENS, CD; B-LYMPHOCYTE SUBSETS; BACTERIAL PROTEINS; FECES; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTEGRINS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTE COUNT; MIDDLE AGED; SEQUENCE DELETION; SHIGELLA FLEXNERI; SHIGELLA VACCINES; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 79954615124     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.02.003     Document Type: Article

References (44)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., Adak G.K., Levine M.M. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 1999, 77:651-666.
2. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 2007, 5:540-553.
3. Pickering L.K. Antimicrobial resistance among enteric pathogens. Semin. Pediatr. Infect. Dis. 2004, 15:71-77.
4. Bioterrorism Agents/Diseases. Center for Disease Control and Prevention Website (2010). Available from: URL: http://www.bt.cdc.gov/agent/agentlist.asp.
5. Bennish M.L., Wojtyniak B.J. Mortality due to shigellosis: community and hospital data. Rev. Infect. Dis. 1991, 13(Suppl 4):S245-S251.
6. Future needs and directions for Shigella vaccines, Weekly Epidemiological Record 81 (2006) 51-58.
7. Kotloff K.L., Pasetti M.F., Barry E.M., Nataro J.P., Wasserman S.S., Sztein M.B., Picking W.D., Levine M.M. Deletion in the Shigella Enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a Phase 1 trial of CVD 1204 and CVD 1208. J. Infect. Dis. 2004, 190:1745-1754.
8. Kotloff K.L., Losonsky G.A., Nataro J.P., Wasserman S.S., Hale T.L., Taylor D.N., Newland J.W., Sadoff J.C., Formal S.B., Levine M.M. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 1995, 13:495-502.
9. Cohen D., Block C., Green M.S., Lowell G., Ofek I. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 1989, 27:162-167.
10. Oaks E.V., Hale T.L., Formal S.B. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect. Immun. 1986, 53:57-63.
11. Oberhelman R.A., Kopecko D.J., Salazar-Lindo E., Gotuzzo E., Buysse J.M., Venkatesan M.M., Yi A., Fernandez-Prada C., Guzman M., Leon-Barua R. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect. Immun. 1991, 59:2341-2350.
12. Barzu S., Nato F., Rouyre S., Mazie J.C., Sansonetti P., Phalipon A. Characterization of B-cell epitopes on IpaB, an invasion- associated antigen of Shigella flexneri: identification of an immunodominant domain recognized during natural infection. Infect. Immun. 1993, 61:3825-3831.
13. Samandari T., Kotloff K.L., Losonsky G.A., Picking W.D., Sansonetti P.J., Levine M.M., Sztein M.B. Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J. Immunol. 2000, 164:2221-2232.
14. Traggiai E., Puzone R., Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003, 21(Suppl 2):S35-S37.
15. Li A., Karnell A., Huan P.T., Cam P.D., Minh N.B., Tram L.N., Quy N.P., Trach D.D., Karlsson K., Lindberg G. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers. Vaccine 1993, 11:180-189.
16. Simon J.K., Wahid R., Maciel M., Picking W.L., Kotloff K.L., Levine M.M., Sztein M.B. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates. Vaccine 2009, 27:565-572.
17. Sztein M.B., Wasserman S.S., Tacket C.O., Edelman R., Hone D., Lindberg A.A., Levine M.M. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 1994, 170:1508-1517.
18. Westphal O., Jann K., Himmelspach K. Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins. Prog. Allergy 1983, 33:9-39.
19. Espina M., Ausar S.F., Middaugh C.R., Baxter M.A., Picking W.D., Picking W.L. Conformational stability and differential structural analysis of LcrV, PcrV, BipD, and SipD from type III secretion systems. Protein Sci. 2007, 16:704-714.
20. Espina M., Olive A.J., Kenjale R., Moore D.S., Ausar S.F., Kaminski R.W., Oaks E.V., Middaugh C.R., Picking W.D., Picking W.L. IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect. Immun. 2006, 74:4391-4400.
21. Harrington A., Darboe N., Kenjale R., Picking W.L., Middaugh C.R., Birket S., Picking W.D. Characterization of the interaction of single tryptophan containing mutants of IpaC from Shigella flexneri with phospholipid membranes. Biochemistry 2006, 45:626-636.
22. Darboe N., Kenjale R., Picking W.L., Picking W.D., Middaugh C.R. Physical characterization of MxiH and PrgI, the needle component of the type III secretion apparatus from Shigella and Salmonella. Protein Sci. 2006, 15:543-552.
23. Birket S.E., Harrington A.T., Espina M., Smith N.D., Terry C.M., Darboe N., Markham A.P., Middaugh C.R., Picking W.L., Picking W.D. Preparation and characterization of translocator/chaperone complexes and their component proteins from Shigella flexneri. Biochemistry 2007, 46:8128-8137.
24. Van De Verg L., Herrington D.A., Murphy J.R., Wasserman S.S., Formal S.B., Levine M.M. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect. Immun. 1990, 58:2002-2004.
25. Crotty S., Aubert R.D., Glidewell J., Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 2004, 286:111-122.
26. Parsot C. Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol. Lett. 2005, 252:11-18.
27. Zhang L., Wang Y., Olive A.J., Smith N.D., Picking W.D., De Guzman R.N., Picking W.L. Identification of the MxiH needle protein residues responsible for anchoring invasion plasmid antigen D to the type III secretion needle tip. J. Biol. Chem. 2007, 282:32144-32151.
28. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., Zheng N.Y., Mays I., Garman L., Helms C., James J., Air G.M., Capra J.D., Ahmed R., Wilson P.C. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
29. Avery D.T., Ellyard J.I., Mackay F., Corcoran L.M., Hodgkin P.D., Tangye S.G. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J. Immunol. 2005, 174:4034-4042.
30. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25:5467-5484.
31. Brandtzaeg P. The mucosal immune system and its integration with the mammary glands. J. Pediatr. 2010, 156:S8-S15.
32. Tarlinton D. B-cell memory: are subsets necessary?. Nat. Rev. Immunol. 2006, 6:785-790.
33. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 2003, 171:4969-4973.
34. Rojas O.L., Caicedo L., Guzman C., Rodriguez L.S., Castaneda J., Uribe L., Andrade Y., Pinzon R., Narvaez C.F., Lozano J.M., De V.B., Franco M.A., Angel J. Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine. Viral Immunol. 2007, 20:300-311.
35. Clutterbuck E.A., Salt P., Oh S., Marchant A., Beverley P., Pollard A.J. The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology 2006, 119:328-337.
36. Kelly D.F., Snape M.D., Clutterbuck E.A., Green S., Snowden C., Diggle L., Yu L.M., Borkowski A., Moxon E.R., Pollard A.J. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006, 108:2642-2647.
37. Harris A.M., Bhuiyan M.S., Chowdhury F., Khan A.I., Hossain A., Kendall E.A., Rahman A., LaRocque R.C., Wrammert J., Ryan E.T., Qadri F., Calderwood S.B., Harris J.B. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect. Immun. 2009, 77:3850-3856.
38. Kotloff K.L., Nataro J.P., Losonsky G.A., Wasserman S.S., Hale T.L., Taylor D.N., Sadoff J.C., Levine M.M. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 1995, 13:1488-1494.
39. Nanan R., Heinrich D., Frosch M., Kreth H.W. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine 2001, 20:498-504.
40. Tuaillon E., Tabaa Y.A., Petitjean G., Huguet M.F., Pajeaux G., Fondere J.M., Ponseille B., Ducos J., Blanc P., Vendrell J.P. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay. J. Immunol. Methods 2006, 315:144-152.
41. Jaimes M.C., Rojas O.L., Kunkel E.J., Lazarus N.H., Soler D., Butcher E.C., Bass D., Angel J., Franco M.A., Greenberg H.B. Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J. Virol. 2004, 78:10967-10976.
42. Boullier S., Tanguy M., Kadaoui K.A., Caubet C., Sansonetti P., Corthesy B., Phalipon A. Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J. Immunol. 2009, 183:5879-5885.
43. Mel D., Gangarosa E.J., Radovanovic M.L., Arsic B.L., Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull. World Health Organ. 1971, 45:457-464.
44. Mel D.M., Arsic B.L., Radovanovic M.L., Litvinjenko S.A. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol. Acad. Sci. Hung. 1974, 21:109-114.